Eliem Therapeutics Inc.

NASDAQ: ELYM · Real-Time Price · USD
5.11
-0.05 (-0.97%)
At close: Oct 02, 2024, 10:00 PM

Eliem Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Gross Profit
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Income
-23.02M -69.18M -11.73M -4.71M -3M -5.12M -5M -6.71M -23.44M -9.55M -8.75M -13.7M -13.13M -10.7M -9.38M -8.71M -6.88M
Interest Income
n/a -2.69M n/a n/a 1.34M 1.35M 1.26M 1.11K 409.00 n/a 383K n/a n/a n/a n/a n/a n/a
Pretax Income
-20.78M -13.67M -8.89M -54.89M -1.7M -3.64M -3.97M -5.22M -22.29M -7.76M -9.68M -14.6M -13.2M -10.54M -9.62M -8.72M -18.6M
Net Income
-20.78M -13.67M -8.89M -54.89M -1.7M -3.64M -3.97M -5.22M -21.14M -5.97M -9.68M -15.49M -13.28M -10.54M -9.62M -8.72M -18.6M
Selling & General & Admin
5.69M 8.45M 5.49M 3.67M 1.91M 2M 2.13M 3.03M 17.72M 4.63M 4.49M 4.93M 4.87M 3.82M 3.39M 2.91M 2.22M
Research & Development
17.33M 8.91M 6.09M 1.05M 1.09M 3.13M 2.88M 3.69M 5.72M 4.93M 4.26M 8.77M 8.26M 6.88M 5.99M 5.79M 4.66M
Other Expenses
n/a 51.82M 153K n/a n/a n/a n/a n/a n/a n/a n/a n/a 85K 60K 20K n/a n/a
Operating Expenses
23.02M 69.18M 11.73M 4.71M 3M 5.12M 5M 6.71M 23.44M 9.55M 8.75M 13.7M 13.13M 10.7M 9.38M 8.71M 6.88M
Interest Expense
n/a -1.15M n/a n/a n/a 1.15M n/a n/a n/a n/a n/a 1.64M 229K n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
n/a 69.18M 11.73M 4.71M 3M 5.12M 5M 6.71M 23.44M 9.55M 8.75M 13.7M 13.13M 10.7M 9.38M 8.71M 6.88M
Income Tax Expense
n/a 3.01M n/a n/a n/a -3.06K -4.78K n/a -1.15M -1.79M n/a 895K 72K n/a n/a n/a n/a
Shares Outstanding (Basic)
67.46M 48.16M 67.01M 30.35M 27.64M 27.7M 27.07M 26.84M 26.49M 26.37M 26.34M 26.3M 26.24M 26.23M 15.59M 23.46M 11.66M
Shares Outstanding (Diluted)
67.46M 48.16M 67.01M 30.35M 27.64M 27.7M 27.07M 26.84M 26.49M 26.37M 26.34M 26.3M 26.24M 26.23M 15.59M 23.46M 11.66M
EPS (Basic)
-0.31 0.47 -0.13 -1.81 -0.06 -0.13 -0.15 -0.19 -0.8 -0.23 -0.37 -0.59 -0.51 -0.4 -0.62 -0.37 -1.6
EPS (Diluted)
-0.31 0.47 -0.13 -1.81 -0.06 -0.13 -0.15 -0.19 -0.8 -0.23 -0.37 -0.59 -0.51 -0.4 -0.62 -0.37 -1.6
EBITDA
-23.02M -17.87M -11.73M -56.37M -3M -5.12M -5M -6.71M -23.44M -6.15M -8.75M -13.7M -13.13M -10.7M -9.38M -8.71M -6.88M
EBIT
n/a 64.5M -11.73M -56.37M -3M -5.12M -5M -6.71M -23.44M -9.55M -8.75M -13.7M -13.13M -10.7M -9.38M -8.71M -6.88M
Depreciation & Amortization
n/a -6.06M n/a n/a 3M 3.06M 4.78M 5.98M 7.65M 9.55M 8.75M 13.7M 13.13M 10.7M 9.38M 8.71M 6.88M